VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

A small Italian study has found an Ozempic-style drug can halve the number of migraine days suffered in a month.